Uric acid
(Synonyms: 尿酸) 目录号 : GC33827Uric Acid (2,6,8-Trioxypurine, 2,6,8-Trihydroxypurine, 2,6,8-Trioxopurine), a normal component of urine, is a product of the metabolic breakdown of purine nucleotides.
Cas No.:69-93-2
Sample solution is provided at 25 µL, 10mM.
Uric Acid (2,6,8-Trioxypurine, 2,6,8-Trihydroxypurine, 2,6,8-Trioxopurine), a normal component of urine, is a product of the metabolic breakdown of purine nucleotides.
Uric acid activates NFκB in a variety of cell culture models including proximal tubular cells. Uric acid suppresses 1-α hydroxylase mRNA and protein expression in dose dependent and time dependent manner[1].
Uric acid is synthesized mainly in the liver, intestines and the vascular endothelium as the end product of an exogenous pool of purines, and endogenously from damaged, dying and dead cells, whereby nucleic acids, adenine and guanine, are degraded into uric acid. Uric acid is a strong reactive oxygen species (ROS) and peroxynitrite scavenger and antioxidant. Uric acid may exert fundamental roles in tissue healing via initiating the inflammatory process that is necessary for tissue repair, scavenging oxygen free radicals, and mobilizing progenitor endothelial cells[2].
[1] Chen W, et al. Metabolism. 2014, 63(1):150-60. [2] Rashika El Ridi, et al. J Adv Res. 2017, 8(5): 487-493.
Cell experiment: |
Human colon carcinoma cells (Caco-2) are used and grown in Eagle’s minimum essential medium supplemented with 10% FBS, 1% non-essential amino acid mixture, and 1% Pen-Strep at 37°C in a humidified atmosphere with 5% CO2. Caco-2 cells are incubated with indomethacin in the presence or absence of Uric acid for 24 or 48 hours[1]. |
Animal experiment: |
To evaluate the effect of oral administration of Uric acid on NSAID-induced enteropathy, mice are given Uric acid (2.5, 10, 25, 100, or 250 mg/kg body weight) suspended in 0.5% carboxymethyl cellulose orally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment. To evaluate the effect of intraperitoneal administration of inosinic acid plus potassium oxonate on NSAID-induced enteropathy, mice are given inosinic acid (500 mg/kg body weight) plus potassium oxonate (250 mg/kg body weight) 24 intraperitoneally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment[1]. |
References: [1]. Yasutake Y, et al. Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. J Gastroenterol Hepatol. 2017 Nov;32(11):1839-1845. |
Cas No. | 69-93-2 | SDF | |
别名 | 尿酸 | ||
Canonical SMILES | O=C(N1)NC2=C(NC(N2)=O)C1=O | ||
分子式 | C5H4N4O3 | 分子量 | 168.11 |
溶解度 | < 1 mg/mL in DMSO (insoluble or slightly soluble); 3mg/mL in Water (ultrasonic and adjust pH to 10 with 1M NaOH). | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.9485 mL | 29.7424 mL | 59.4849 mL |
5 mM | 1.1897 mL | 5.9485 mL | 11.897 mL |
10 mM | 0.5948 mL | 2.9742 mL | 5.9485 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet